Understanding how IL-2 helps regulate immune tolerance
Mechanisms of Il-2-mediated immune tolerance
['FUNDING_R21'] · BENAROYA RESEARCH INST AT VIRGINIA MASON · NIH-10909803
This study is looking at how a special treatment can help boost a type of immune cell that keeps your body from attacking itself, which could lead to new ways to manage autoimmune diseases and improve your immune health.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BENAROYA RESEARCH INST AT VIRGINIA MASON (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-10909803 on ClinicalTrials.gov |
What this research studies
This research investigates the role of IL-2 in the development and function of regulatory T cells, which are crucial for maintaining immune tolerance. By using a specially designed IL-2 mutein that selectively targets these regulatory T cells, the study aims to enhance their abundance and function in the body. The approach involves examining how this treatment can suppress autoimmune responses and promote long-lasting protection against autoimmune diseases. Patients may benefit from insights into new therapeutic strategies that could improve their immune regulation.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from autoimmune diseases who may benefit from improved immune regulation.
Not a fit: Patients with non-autoimmune conditions or those who do not have a significant immune tolerance issue may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively manage autoimmune diseases by enhancing the body's natural immune tolerance.
How similar studies have performed: Previous research has shown promising results with similar approaches targeting regulatory T cells, indicating potential for success in this novel application.
Where this research is happening
SEATTLE, UNITED STATES
- BENAROYA RESEARCH INST AT VIRGINIA MASON — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CAMPBELL, DANIEL J — BENAROYA RESEARCH INST AT VIRGINIA MASON
- Study coordinator: CAMPBELL, DANIEL J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Autoimmune Diseases